In Brief: Shingrix for Immunocompromised Adults
Date: August 23, 2021 Issue #: 1631Summary: The FDA has licensed the adjuvanted, recombinant varicella zoster virus (VZV) vaccineShingrix (GSK) for prevention of herpes zoster (shingles) in adults of any age who are or will be at elevated risk because of disease- or therapy-induced immunodeficiency or immunosuppression.Shingrix has been licensed for herpes zoster prevention in adults ≥50 years old since 2017.1 It is the only VZV vaccine currently available in the US;Zostavax, a live-attenuated VZV vaccine, was withdrawn from the market in 2020.
CONCLUSIONS: More than half of the sub-sample reported not knowing about shingles vaccine, therefore, opportunities to increase awareness should be prioritized. Since provider recommendation and flu vaccination receipt had the greatest odds of increasing shingles vaccination, standard practice should include adding shingles to flu vaccine recommendations for age-eligible patients.PMID:34625290 | DOI:10.1016/j.vaccine.2021.09.032
Background. Immunization of varicella-zoster virus (VZV)-seronegative solid organ transplant (SOT) patients using the live-attenuated varicella vaccine is generally contraindicated, leaving no widely applicable immunization option. The recombinant subunit herpes zoster vaccine (RZV) is indicated for VZV-seropositive persons to prevent shingles but could potentially also protect VZV-seronegative persons against varicella. We performed a safety and immunogenicity evaluation of RZV in VZV-seronegative SOT recipients as an option for protection. Methods. VZV-seronegative adult SOT patients with no history of varicel...
CONCLUSION: This trial informs safety concerns related to use of live virus vaccines in patients receiving biologics.PRIMARY FUNDING SOURCE: The National Institute of Arthritis and Musculoskeletal and Skin Diseases and the American College of Rheumatology.PMID:34570596 | DOI:10.7326/M20-6928
J Fam Pract. 2021 Jul;70(6S):S13-S18. doi: 10.12788/jfp.0218.ABSTRACTAt the end of the activity, participants will be able to: • Characterize the burden of herpes zoster infections. • Recommend the recombinant zoster vaccine to patients in accordance with guidance from the Advisory Committee on Immunization Practices. • Implement strategies to increase patient acceptance of herpes zoster and other vaccinations. • Use available resources to increase awareness among patients about the importance and safety of recommended vaccinations.PMID:34432619 | DOI:10.12788/jfp.0218